REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Two-year data were published in The Lancet in a paper titled "Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study." These positive study results informed the ongoing pivotal trials of ABBV-RGX-314, a potential one-time gene therapy, for the treatment of wet AMD.
REGENXBIO Inc.（納斯達克股票代碼：RGNX）今天宣佈公佈了I/IIa期試驗的結果，該試驗評估了用於治療溼性年齡相關性黃斑變性（溼性AMD）的單劑量視網膜下層 ABBV-RGX-314 的安全性和耐受性。兩年的數據發佈於 這個 柳葉刀 在一篇題爲 “通過視網膜下輸送 RGX-314 治療新生血管年齡相關性黃斑變性的基因療法：1/2a 期劑量遞增研究” 的論文中。這些積極的研究結果爲正在進行的用於治療溼性 AMD 的 ABBV-RGX-314（一種潛在的一次性基因療法）的關鍵試驗提供了信息。